Veracyte, Inc. specializes in the discovery, development, and commercialization of advanced genomic diagnostic tests across the care continuum. The company's principal business segments include testing services, which account for over 90% of its revenue, alongside product sales and biopharmaceutical data collaborations. Key offerings include the Afirma Genomic Sequencing Classifier for thyroid nodules, the Decipher Prostate and Bladder Genomic Classifiers, and the Prosigna Breast Cancer Assay. By leveraging its proprietary nCounter analysis system and extensive whole-transcriptome database, Veracyte empowers physicians with precise diagnostic and prognostic data. Headquartered in South San Francisco, California, the company operates CLIA-certified laboratories to process patient samples domestically. Additionally, Veracyte distributes its in vitro diagnostic (IVD) kits globally to hospitals and regional labs, enabling localized testing for international markets.
